摘要
目的:探讨^(125)I植入联合经导管动脉化疗栓塞(TACE)治疗原发性肝癌的效果及对血清可溶性B7-H4、血管内皮细胞生长因子(VEGF)、癌坯抗原(CEA)、可溶性白细胞介素-2受体(sIL-2R)水平的影响。方法:选取118例原发性肝癌患者,收治时间2012年8月至2014年10月,采用随机数字表法分为联合组和对照组各59例,联合组应用TACE+^(125)I植入治疗,对照组仅采取TACE治疗,两组其余治疗方法保持一致。结果:联合组的缓解率79.68%显著的高于对照组的58.93%(P<0.05);联合组的总有效率94.44%与对照组的91.07%比较差异无统计学意义(P>0.05);治疗前,两组患者的血清B7-H4、VEGF、CEA、sIL-2R水平差异无统计学意义(P>0.05);治疗后,联合组的血清B7-H4、VEGF、CEA、sIL-2R水平均显著的低于对照组(P<0.05);联合组的1年、2年生存率81.48%、62.96%与对照组的76.79%、46.43%比较差异均无统计学意义(P>0.05);联合组的3年生存率42.59%高于对照组的23.21%(P<0.05)。结论:^(125)I植入联合TACE治疗原发性肝癌的效果优于单用TACE,并且可显著降低血清肿瘤标记物水平。
Objective:To investigate the 125I implantation combined with transcatheter arterial chemoembolization(TACE)for the treatment of primary hepatocellular carcinoma growth factor on serum B7-H4 and vascular endothelial cells(VEGF),cancer antigen blank(CEA)and soluble interleukin-2 receptor(sIL-2R)effect and its effect.Methods:118 cases primary liver cancer patients admitted to our hospital were randomly divided into combined group and control group with 59 cases in each group,combined application of TACE+125 I implantation,the control group only take TACE treatment,the remaining two treatments were consistent.Results:Remission rate in combined group 79.68%was significantly higher than that of control group 58.93%(P<0.05);no significant group in the total efficiency of 94.44%and 91.07%in the control group(P>0.05);the difference was not statistically significant before treatment,two groups of patients with serum B7-H4,VEGF,CEA,sIL-2R level differences(P>0.05)after treatment;the combination group,serum B7-H4,VEGF,CEA and sIL-2R levels were significantly lower than the control group(P<0.05);compared with the group of 1 years and 2 years survival rate was 81.48%,62.96%,46.43%and 76.79%in the control group,there were no significant differences(P>0.05);group 3 years survival rate was 42.59%higher than that of the control group of 23.21%(P<0.05).Conclusion:The effect of 125 I implantation combined with TACE in the treatment of primary liver cancer is better than that of TACE alone,and has better effect on serum tumor markers.
作者
韩洪武
李镝
Han Hongwu;Li Di(Department of Radiology,Jinzhou Central Hospital in Liaoning Province,Jinzhou 121000)
出处
《陕西医学杂志》
CAS
2018年第2期202-205,共4页
Shaanxi Medical Journal
基金
辽宁省教育厅科学研究一般项目(L2013336)
关键词
肝肿瘤/治疗
肝动脉
栓塞
治疗性
@125I粒子
Liver neoplasms/therapy
Hepatic artery
Embolization,therapeutic
@125I particles
